THE NIGHTVIEW FUND (NITE) Stock News
NYSEARCA:NITE - NYSE Arca - US14064D4850 - ETF - Currency: USD
NITE Latest News, Press Relases and Analysis
Tesla's Energy Division Shines, But ETF Risks Mount Amid Broader Challenges
Tesla stock may still be one of Wall Street's most-watched, but with a 33% drop YTD, investors are navigating volatility and tariff threats in ETFs like TESL, NITE, and VCR.
Target Unveils $15 Billion Sales Growth Strategy With Focus on Digital Expansion
Target plans to drive $15B in sales growth by 2030 by expanding product categories, digital marketplace, owned brands, stores, loyalty program, and same-day services.
Biogen Leads List of Drugmakers Left to Make a Needed M&A Splash
Biotechnology investors who have popped corks to celebrate the wave of deals in the first half of 2019 can set their sights on the remainder of companies that have stayed passive to start the year.
Gene-Therapy Firm UniQure Explores Options Including Sale
UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said.
Biogen completes Nightstar buy
Biogen (NASDAQ:BIIB) has completed its acquisition of Nightstar Therapeutics (NASDAQ:NITE) for ~$800M.As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as we
Biogen acquires Nightstar for $800M
Biogen (NASDAQ:BIIB) has completed its acquisition of Nightstar Therapeutics (NASDAQ:NITE) for ~$800M.As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as we
Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday.
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition
Celgene Stock Breaks Out As Bristol Grabs Key Merger Endorsement
Celgene stock broke out Friday after two proxy advisory firms voted in favor of Bristol-Myers Squibb's looming Celgene acquisition.
Biogen Stock Fell Too Far on Unfortunate News
BIIB stopping its Alzheimer's trials hurt. But for long-term investors, the dip has opened up an opportunity in Biogen stock
Biogen Crashes On Alzheimer's Flop — Is Its Remaining Pipeline A Dud?
Biogen stock crashed Thursday — taking biotech stocks with it — after it scrapped a pair of studies testing experimental Alzheimer's treatment aducanumab.
Sideways Market Vexes Traders: Biotech Stocks are Fading
The 2019 rally is fading with few clues as to what comes next. The narrative gets more complicated once a slower global economic outlook gets factored into the fundamentals.
How Much Does Biogen Gain From Its $800 Million Gene Therapy Buyout?
Biogen's pending acquisition of gene therapy player Nightstar only offers a "modest pipeline boost," an analyst said Tuesday. Biogen stock rose a fraction.
Mentions: BIIB